Handa Pharmaceuticals is scheduled to list on the Taipei Exchange on December 23. The company will issue 11,200 new shares, with 8,000 shares designated for competitive bidding from December 8 to 10 at a floor price of NT$72.33.

Financial Performance:

• Revenue Growth: Handa achieved a turnaround in 2024, reporting an EPS of NT$3.35. For the first three quarters of 2025, revenue reached **NT$1.429 billion** with an EPS of NT$3.76, driven largely by 505(b)(2) new drugs, which now account for over 60% of total revenue.
• Product Pipeline: Successful North American launches include Quetiapine XR, Dexlansoprazole DR, and the 505(b)(2) drug Tascenso. In October 2025, the U.S. subsidiary Handa Therapeutics launched Phyrago™.
• Oncology Pipeline: The multi-target cancer drug HND-039 submitted its NDA to the U.S. FDA in September 2025, with a target action date (PDUFA) of July 29, 2026. HND-039 targets a US$1.79 billion market where no generic competition is expected until at least 2030–2031.

Resource: 漢達23日掛牌上櫃 雙引擎拉動獲利穩增